{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:35:19Z","timestamp":1791250519231,"version":"4.1.0"},"reference-count":89,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for second-line therapy. Splenectomy continues to provide the highest cure rate (60%-70% at 5+ years). Nonetheless, splenectomy is invasive, irreversible, associated with postoperative complications, and its outcome is currently unpredictable, leading some physicians and patients toward postponement and use of alternative approaches. An important predicament is the lack of studies comparing second-line options to splenectomy and to each other. Furthermore, some adults will improve spontaneously within 1-2 years. Rituximab has been given to more than 1 million patients worldwide, is generally well tolerated, and its short-term toxicity is acceptable. In adults with ITP, 40% of patients are complete responders at one year and 20% remain responders at 3-5 years. Newer approaches to using rituximab are under study. TPO-RAs induce platelet counts &gt; 50 000\/\u03bcL in 60%-90% of adults with ITP, are well-tolerated, and show relatively little short-term toxicity. The fraction of TPO-RA\u2013treated patients who will be treatment-free after 12-24 months of therapy is unknown but likely to be low. As each approach has advantages and disadvantages, treatment needs to be individualized, and patient participation in decision-making is paramount.<\/jats:p>","DOI":"10.1182\/blood-2011-12-309153","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T15:46:02Z","timestamp":1340811962000},"page":"960-969","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":188,"title":["How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment"],"prefix":"10.1182","volume":"120","author":[{"given":"Waleed","family":"Ghanima","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Weill Cornell Medical College, New York, NY;"},{"name":"Department of Internal Medicine, \u00d8stfold Hospital Trust Fredrikstad, Fredrikstad, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, UPEC, Cr\u00e9teil, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Cines","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine and"},{"name":"Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Bussel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111809412465800_B1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.21029","article-title":"Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century.","volume":"83","author":"Dolan","year":"2008","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111809412465800_B2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111809412465800_B3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"issue":"16","key":"2019111809412465800_B4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111809412465800_B5","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111809412465800_B6","first-page":"1041","article-title":"The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy.","volume":"91","author":"Sailer","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111809412465800_B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.21109","article-title":"Is splenectomy still the gold standard for the treatment of chronic ITP?","volume":"83","author":"Rodeghiero","year":"2008","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111809412465800_B8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia.","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2019111809412465800_B9","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111809412465800_B10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOH.0b013e3282ba5552","article-title":"Pathogenesis of chronic immune thrombocytopenic purpura.","volume":"14","author":"Cines","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2019111809412465800_B11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111809412465800_B12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111809412465800_B13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production.","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111809412465800_B14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"issue":"26","key":"2019111809412465800_B15","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity.","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111809412465800_B16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2005.05542.x","article-title":"Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura.","volume":"129","author":"Rajan","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111809412465800_B17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111809412465800_B18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"},{"issue":"5","key":"2019111809412465800_B19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MOH.0b013e3282b9748f","article-title":"Immune thrombocytopenic purpura in adults.","volume":"14","author":"Godeau","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2019111809412465800_B20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3324\/haematol.2009.007674","article-title":"Definition, diagnosis and treatment of immune thrombocytopenic purpura.","volume":"94","author":"George","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111809412465800_B21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111809412465800_B22","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","article-title":"How I treat idiopathic thrombocytopenic purpura. (ITP).","volume":"106","author":"Cines","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111809412465800_B23","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111809412465800_B24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM199411033311807","article-title":"Chronic idiopathic thrombocytopenic purpura.","volume":"331","author":"George","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111809412465800_B25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111809412465800_B26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.","volume":"349","author":"Cheng","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111809412465800_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3687.3687","article-title":"High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. American Society of Hematology Congress [abstract].","volume":"116","author":"Bae","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111809412465800_B28","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V99.6.1922","article-title":"Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?","volume":"99","author":"Cooper","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111809412465800_B29","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111809412465800_B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"key":"2019111809412465800_B31","first-page":"72","article-title":"Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.","volume":"90","author":"Vianelli","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"2019111809412465800_B32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.10253","article-title":"Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).","volume":"72","author":"Schwartz","year":"2003","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111809412465800_B33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.21501","article-title":"Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review.","volume":"84","author":"Mikhael","year":"2009","journal-title":"Am J Hematol"},{"issue":"9610","key":"2019111809412465800_B34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"9664","key":"2019111809412465800_B35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"2019111809412465800_B36","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.","volume":"89","author":"Scaradavou","year":"1997","journal-title":"Blood"},{"issue":"44","key":"2019111809412465800_B37","first-page":"2263","article-title":"[Splenectomy by the laparoscopic approach: report of a case].","volume":"20","author":"Delaitre","year":"1991","journal-title":"Presse Med"},{"issue":"2","key":"2019111809412465800_B38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1658-3876(10)50038-4","article-title":"Systemic thromboembolic complications after laparoscopic splenectomy for idiopathic thrombocytopenic purpura in comparison to open surgery in the absence of anticoagulant prophylaxis.","volume":"3","author":"Mohamed","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"2019111809412465800_B39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0039-6060(03)00312-X","article-title":"Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications.","volume":"134","author":"Winslow","year":"2003","journal-title":"Surgery"},{"issue":"1","key":"2019111809412465800_B40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00464-010-1171-2","article-title":"Computed tomography to detect accessory spleens before laparoscopic splenectomy: is it necessary?","volume":"25","author":"Quah","year":"2011","journal-title":"Surg Endosc"},{"issue":"10","key":"2019111809412465800_B41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s004649900221","article-title":"Laparoscopic splenectomy for ITP: the gold standard.","volume":"10","author":"Friedman","year":"1996","journal-title":"Surg Endosc"},{"issue":"6","key":"2019111809412465800_B42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0003-3944(00)00236-4","article-title":"[Laparoscopic splenectomy for hematologic diseases: study of 275 cases. French Society of Laparoscopic Surgery].","volume":"125","author":"Delaitre","year":"2000","journal-title":"Ann Chir"},{"issue":"2","key":"2019111809412465800_B43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.20433","article-title":"Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count.","volume":"80","author":"Keidar","year":"2005","journal-title":"Am J Hematol"},{"issue":"14","key":"2019111809412465800_B44","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood-2009-04-210112","article-title":"Vascular complications after splenectomy for hematologic disorders.","volume":"114","author":"Crary","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111809412465800_B45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00277-010-1087-x","article-title":"Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis.","volume":"90","author":"Khellaf","year":"2011","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111809412465800_B46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2010.03.003","article-title":"Thrombopoietic agents in immune thrombocytopenia.","volume":"47","author":"Ghanima","year":"2010","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111809412465800_B47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab.","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111809412465800_B48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2141.1998.01006.x","article-title":"Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia.","volume":"103","author":"Valat","year":"1998","journal-title":"Br J Haematol"},{"key":"2019111809412465800_B49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(00)90113-6","article-title":"The spleen: anatomy and anatomical function.","volume":"37","author":"Chadburn","year":"2000","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111809412465800_B50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2010.08377.x","article-title":"Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry.","volume":"151","author":"Sarpatwari","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111809412465800_B51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2010.1.385","article-title":"Evidence-based mini-review: is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?","volume":"2010","author":"Cuker","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111809412465800_B52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2009.10.003","article-title":"Mortality risk in splenectomised patients: a Danish population-based cohort study.","volume":"21","author":"Yong","year":"2010","journal-title":"Eur J Intern Med"},{"issue":"8","key":"2019111809412465800_B53","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019111809412465800_B54","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"issue":"5","key":"2019111809412465800_B55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.thromres.2007.12.022","article-title":"Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP.","volume":"122","author":"Fontana","year":"2008","journal-title":"Thromb Res"},{"issue":"1","key":"2019111809412465800_B56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/msy.2003.204","article-title":"Open versus laparoscopic splenectomy for idiopathic thrombocytopenic purpura: clinical and economic analysis.","volume":"134","author":"Cordera","year":"2003","journal-title":"Surgery"},{"issue":"6","key":"2019111809412465800_B57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1538-7836.2010.03849.x","article-title":"Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study.","volume":"8","author":"Thomsen","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111809412465800_B58","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1046\/j.1365-2168.2000.01514.x","article-title":"Diagnosis and treatment of portal vein thrombosis following splenectomy.","volume":"87","author":"van't Riet","year":"2000","journal-title":"Br J Surg"},{"issue":"6","key":"2019111809412465800_B59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.7326\/0003-4819-130-6-199903160-00014","article-title":"Pulmonary hypertension after splenectomy?","volume":"130","author":"Hoeper","year":"1999","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111809412465800_B60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0049-3848(02)00337-7","article-title":"Vascular dementia in patients with immune thrombocytopenic purpura.","volume":"107","author":"Ahn","year":"2002","journal-title":"Thromb Res"},{"issue":"1","key":"2019111809412465800_B61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019111809412465800_B62","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111809412465800_B63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01100.x","article-title":"Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.","volume":"81","author":"Medeot","year":"2008","journal-title":"Eur J Haematol"},{"key":"2019111809412465800_B64","first-page":"95","article-title":"The combination of three dexamethasone cycles and rituximab yields high response rate in previously treated immune thrombocytopenia (ITP) [abstract].","volume":"96","author":"Ghanima","year":"2011","journal-title":"Haematologica"},{"key":"2019111809412465800_B65","article-title":"Rituximab maintenance treatment in immune mediated thrombocytopenia (ITP) including Evans syndrome [abstract].","volume":"116","author":"Mahler","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111809412465800_B66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","article-title":"Rituximab in the treatment of autoimmune haematological disorders.","volume":"141","author":"Garvey","year":"2008","journal-title":"Br J Haematol"},{"issue":"26","key":"2019111809412465800_B67","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"2019111809412465800_B68","first-page":"224","article-title":"Subcutaneous injections of low-dose anti-CD20 veltuzumab for patients with relapsed immune thrombocytopenia (ITP) [abstract].","volume":"96","author":"Liebmann","year":"2011","journal-title":"Haematologica"},{"key":"2019111809412465800_B69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia.","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"issue":"12","key":"2019111809412465800_B70","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"2019111809412465800_B71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens.","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"issue":"14","key":"2019111809412465800_B72","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"2019111809412465800_B73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2415.2415","article-title":"Long term follow up analysis following front line therapy with dexamethasone or dexamethasone plus rituximab in adults with primary immune thrombocytopenia [abstract].","volume":"114","author":"Zaja","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111809412465800_B74","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia.","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111809412465800_B75","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"2019111809412465800_B76","first-page":"98","article-title":"Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim: four European case studies [abstract].","volume":"96","author":"Newland","year":"2010","journal-title":"Haemtologica"},{"issue":"2","key":"2019111809412465800_B77","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2011.08845.x","article-title":"Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.","volume":"155","author":"Ghanima","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111809412465800_B78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/modpathol.2011.128","article-title":"Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.","volume":"25","author":"Boiocchi","year":"2012","journal-title":"Mod Pathol"},{"key":"2019111809412465800_B79","article-title":"Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases [abstract].","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood (Annual Meeting Abstracts)"},{"issue":"22","key":"2019111809412465800_B80","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2019111809412465800_B81","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","article-title":"Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.","volume":"118","author":"Khellaf","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111809412465800_B82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.seminhematol.2010.03.002","article-title":"Toxicities of the thrombopoietic growth factors.","volume":"47","author":"Cuker","year":"2010","journal-title":"Semin Hematol"},{"issue":"12","key":"2019111809412465800_B83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-010-1066-2","article-title":"Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate.","volume":"89","author":"Stasi","year":"2010","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111809412465800_B84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00277-010-1047-5","article-title":"Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark.","volume":"90","author":"Jensen","year":"2011","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111809412465800_B85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V77.1.31.31","article-title":"High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura.","volume":"77","author":"Cortelazzo","year":"1991","journal-title":"Blood"},{"issue":"9","key":"2019111809412465800_B86","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111809412465800_B87","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"key":"2019111809412465800_B88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000290758","article-title":"[Diagnosis and therapy of autoimmune thrombocytopenia: recommendations of a joint Expert Group of DGHO, DGTI, DTH].","volume":"33","author":"Matzdorff","year":"2010","journal-title":"Onkologie"},{"issue":"4","key":"2019111809412465800_B89","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.","volume":"120","author":"British Committee for Standards in Haematology General Haematology Task Force","year":"2003","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/960\/1362593\/zh803112000960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/960\/1362593\/zh803112000960.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:36:56Z","timestamp":1574091416000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/5\/960\/30278\/How-I-treat-immune-thrombocytopenia-the-choice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,2]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-309153","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,2]]}}}